查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球控释给药市场 - 2023-2030 年
市场调查报告书
商品编码
1316273

全球控释给药市场 - 2023-2030 年

Global Controlled Release Drug Delivery Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球控释给药市场规模达到 509 亿美元，预计到 2030 年将实现利润丰厚的增长，达到 1013 亿美元。在预测期内（2023-2030 年），全球控释给药市场预计将呈现 9.2% 的复合年增长率。

控释系统可实现药物的长期持续、有序释放。这种调节释放有助于将治疗药物浓度保持在适当范围内，最大限度地提高疗效。它可以减少给药次数，保证持续供药，从而提高患者的依从性，达到更好的治疗效果。

此外，由于制药公司积极应对不断变化的市场需求，并持续投资开发控释给药方法，因此极大地促进了需求。

市场动态

老年人口和儿童人口的增加将推动市场增长

全球老年人口和儿童人口的不断增长是推动市场扩大的主要原因之一，这主要是由于这些年龄段的人普遍不遵从处方治疗。老年人的身体、精神和生物功能受损，影响了他们的用药。

例如，世卫组织指出，所有国家在确保其卫生和社会系统做好准备利用这一人口结构转变方面都面临重大挑战。到 2050 年，80% 的老年人将生活在中低收入国家。人口老龄化的速度大大高于过去。

2020 年，60 岁及以上人口的数量将超过 5 岁以下的年轻人。从 2015 年到 2050 年，全球 60 岁以上人口的比例将增加近一倍，从 12%增至 22%。因此，不断增长的老年人口将有助于推动市场扩张。

主要公司不断加强的倡议和战略也将推动市场增长

据预测，主要企业为应对控释给药不断增长的需求而开展的活动和实施的战略也将推动市场扩张。例如，2020 年 10 月，德国赢创工业集团（Evonik Industries AG）推出了一种口服给药技术 Eudratec Fasteric，该技术可提高口服药物的肠道吸收率，其靶点位于吸收窗口较窄的小肠上段。

此外，该技术可使用传统器械快速高效地加工，并与多种口服剂型兼容，包括多颗粒、片剂和胶囊。市场将因上述因素而扩大。

缺乏按需释放技术将阻碍市场增长

开发按需控释给药系统在技术上具有挑战性。它需要整合复杂的机制，以触发药物释放来响应特定的刺激或外部信号。设计这种能精确控制药物释放速率和剂量的系统非常复杂，通常需要先进的材料和工程技术。

由于需要专门的材料、技术和制造工艺，开发按需控释系统的成本可能很高。此外，这些系统的复杂性可能会增加生产成本，使其更难以负担和广泛使用。因此，上述因素将限制市场的增长。

COVID-19 影响分析

COVID-19 大流行对控释给药领域产生了积极和消极的影响。由于对 COVID-19 疫苗的迫切需求，控释疫苗给药系统的开发受到了极大重视。这些系统旨在提高疫苗疗效、减少所需剂量并改善患者的依从性。

人们一直在努力开发长效疫苗制剂，以提供持续的免疫反应，并消除对频繁加强剂的需求。大流行导致医疗保健和制药研究方面的资金和投资增加。这为控释给药系统的开发创造了新的机会。

俄乌战争影响分析

据估计，俄乌冲突对全球控释给药市场的影响不大，原因是该地区的主要市场参与者较少。不过，在预测期内，原材料进出口的影响预计对全球控释给药市场的增长影响不大。

目 录

第 1 章：研究方法与范围

  • 研究方法
  • 报告的研究目标和范围

第2章：定义和概述

第 3 章：执行摘要

  • 按发布机制分類的片段
  • 按技术划分
  • 按给药途径划分
  • 按地区划分

第 4 章：动态

  • 影响因素
    • 驱动因素
      • 慢性病发病率上升
      • 主要公司采取更多倡议和战略
    • 制约因素
      • 缺乏按需发布
    • 机会
      • 医疗基础设施有限的发展中国家
    • 影响分析

第 5 章：行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情况
    • COVID-19 期间的情景
    • COVID-19 后的情况
  • COVID-19 期间的定价动态
  • 供求关系
  • 大流行期间与市场相关的政府倡议
  • 制造商的战略倡议
  • 结论

第7章：按释放机制分类

  • 聚合物给药系统
  • 活化调节给药系统
    • 渗透压激活给药系统
    • 水动力压力激活给药系统
    • 蒸汽压活化给药
    • 机械激活给药系统
  • 化学激活给药系统
    • pH 活化给药系统
    • 水解激活给药
    • 酶激活给药

第 8 章：按技术分类

  • 沃斯特技术
  • 微胶囊技术
  • 包囊技术
  • 靶向给药
  • 其他

第九章：按给药途径分类

  • 药物洗脱支架
  • 眼部植入物
  • 自动注射器/无针注射器
  • 鼻腔喷雾器
  • 输液泵
  • 其他

第 10 章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 特定地区的主要动态

第 11 章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併与收购分析

第十二章 ：公司简介

  • Johnson and Johnson.
    • 公司概况
    • 产品组合和说明
    • 财务概况
    • 主要发展
  • Coating Place, Inc
  • Corium International, Inc
  • Depomed, Inc
  • Pfizer, Inc
  • Biogen
  • GlaxoSmithKline
  • Novartis
  • Orbis Biosciences, Inc.
  • Merck and Co.

第 13 章 ：附录

简介目录
Product Code: MD1329

Market Overview

The global controlled release drug delivery market reached US$ 50.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 101.3 billion by 2030. The global controlled release drug delivery market is expected to exhibit a CAGR of 9.2% during the forecast period (2023-2030).

Controlled release systems enable the sustained and regulated release of medications over a long period of time. This regulated distribution helps to keep therapeutic medication concentrations within the appropriate range, maximising therapy efficacy. It can increase patient compliance by reducing drug administration frequency and guaranteeing continuous drug supply, resulting in better therapeutic outcomes.

Additionally, pharmaceutical companies, who operate in a fiercely competitive and fragmented industry, have greatly boosted demand as a result of their proactive response to evolving market demands and continued investments in developing controlled-release drug delivery methods.

Market Dynamics

The Increasing Geriatric and Pediatric Population will Drive the Market Growth

The growing geriatric and paediatric population worldwide is one of the primary reasons driving market expansion, owing largely to non-adherence to prescription regimens, which is quite common among these age groups. Geriatric people have impaired physical, mental, and biological functioning, which affect their medication usage.

For instance, according to WHO, all countries have significant challenges in ensuring that their health and social systems are prepared to capitalise on this demographic transformation. By 2050, 80% of the elderly will live in low- and middle-income countries. The population is ageing at a considerably higher rate than in the past.

In 2020, the number of persons aged 60 and more will outnumber youngsters under the age of five. Between 2015 and 2050, the fraction of the global population over the age of 60 will nearly double, from 12% to 22%. As a result, the growing senior population will aid to boost market expansion.

Raising Initiatives And Strategies By the Key Companies also Drive the Market Growth

The increased activities and strategies implemented by key players to deal with the growing demand for controlled release medicine delivery are also predicted to fuel market expansion. For instance, in October 2020, Evonik Industries AG, a German pharmaceutical company, has introduced Eudratec Fasteric, an oral drug delivery technology that improves intestinal absorption for oral drug products that target sites in the upper small intestine with a narrow absorption window.

Furthermore, it can be processed rapidly and efficiently using conventional instruments and is compatible with a wide range of oral dose forms, including multiarticulate, tablets, and capsules. The market will expand as a result of the aforementioned factors.

Lack of On-Demand Release will Hamper the Market Growth

Developing on-demand controlled release drug delivery systems is technically challenging. It requires the integration of sophisticated mechanisms to trigger drug release in response to specific stimuli or external signals. Designing such systems with precise control over drug release rates and dosages is complex and often requires advanced materials and engineering techniques.

Developing on-demand controlled release systems can be costly due to the need for specialized materials, technologies, and manufacturing processes. Additionally, the complexity of these systems may increase the production costs, making them less affordable and accessible for widespread use. Thus, above factors will restrict the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had both positive and negative impacts on the field of controlled release drug delivery. With the urgent need for COVID-19 vaccines, there has been a significant emphasis on developing controlled release vaccine delivery systems. These systems aim to enhance vaccine efficacy, reduce the number of doses required, and improve patient compliance.

Efforts have been made to develop long-acting vaccine formulations that provide sustained immune response and eliminate the need for frequent boosters. The pandemic has led to increased funding and investment in healthcare and pharmaceutical research. This has created new opportunities for the development of controlled release drug delivery systems.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global controlled release drug delivery market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global controlled release drug delivery market growth over the forecast period.

Segment Analysis

The global controlled release drug delivery market is segmented based on release mechanism, technology, route of administration and region.

Auto-injectors/Needle-free injectors from Route of Administration Segment Aaccounts for 30.7% of Market Share Owing to Rising Novel Product Launches

During the projection period, targeted drug delivery is expected to dominate the market. This is mainly due to expanding demand, as well as a growing geriatric and paediatric population. For instance, In 2021, there were about 26.2 million children between the ages of 12 and 17 years old living in the United States. On the other hand, there were about 22.9 million children between the ages of zero and five years old in the country.

Additionally, when compared to typical delivery methods, targeted delivery systems achieve a longer therapeutic effect by delivering medications at the target site at predetermined drug release kinetics. Furthermore, the increasing number of product launches as a result of the increased benefits afforded by targeted delivery are likely to support the segment's growth.

Geographical Analysis

Europe Accounted for Approximately 27.4% of the Market Share

Due to increased R&D efforts and the presence of large pharmaceutical companies in the region. With an increase in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is expected to grow steadily in the next years.

For instance, according to EUROSTAT, In 2020, cancer was the second highest cause of death in the EU, accounting for 1.2 million deaths, or 23.0% of all deaths in the EU. Cancer claimed a greater share of male mortality (24.9%) than female deaths (20.0%). As a result, the previously mentioned factors will dominate market growth.

Competitive Landscape

The major global players in the controlled release drug delivery market include: Johnson and Johnson, Coating Place, Inc, Corium International, Inc, Depomed, Inc, Pfizer, Inc, Biogen, GlaxoSmithKline, Novartis, Orbis Biosciences, Inc., Merck and Co among others.

Why Purchase the Report?

  • To visualize the global controlled release drug delivery market segmentation based on release mechanism, technology, route of administration and region,as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of controlled release drug delivery market-level with all segments.
  • PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available asexcelconsisting of key products of all the major players.

The global controlled release drug delivery market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Release Mechanism
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in prevalence of chronic diseases
      • 4.1.1.2. Raising initiatives and strategies by the key companies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of On-Demand Release
    • 4.1.3. Opportunity
      • 4.1.3.1. Developing countries with limited access to healthcare infrastructure
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Release Mechanism

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
    • 7.1.2. Market Attractiveness Index, By Release Mechanism
  • 7.2. Polymer-based drug delivery system*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Activation modulated drug delivery system
    • 7.3.1. Osmotic pressure activated drug delivery
    • 7.3.2. Hydrodynamic pressure activated drug delivery
    • 7.3.3. Vapor pressure activated drug delivery
    • 7.3.4. Mechanically activated drug delivery
  • 7.4. Chemically activated drug delivery system
    • 7.4.1. pH activated drug delivery
    • 7.4.2. Hydrolysis activated drug delivery
    • 7.4.3. Enzyme activated drug delivery

8. ByTechnology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Wurster technique*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Micro encapsulation
  • 8.4. Coacervation
  • 8.5. Targeted delivery
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Drug-eluting stents*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ocular implants
  • 9.4. Auto-injectors/ Needle-free injectors
  • 9.5. Nasal sprays
  • 9.6. Infusion pumps
  • 9.7. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Johnson and Johnson.*
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Coating Place, Inc
  • 12.3. Corium International, Inc
  • 12.4. Depomed, Inc
  • 12.5. Pfizer, Inc
  • 12.6. Biogen
  • 12.7. GlaxoSmithKline
  • 12.8. Novartis
  • 12.9. Orbis Biosciences, Inc.
  • 12.10. Merck and Co.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us